Ultragenyx Pharmaceutical Inc. has entered into a settlement agreement with Navinta LLC to resolve patent litigation concerning its drug DOJOLVI® (triheptanoin). The lawsuit was initiated in response to Navinta's application to market a generic version of the drug in the United States.
Key Details
- Agreement Terms: Ultragenyx will grant Navinta a non-exclusive, royalty-free license to market its generic version of DOJOLVI®.
- Timeline: The license permits Navinta to begin marketing its generic product on January 1, 2033. This date could be extended to July 1, 2033, if DOJOLVI® is granted pediatric exclusivity.
- Ongoing Litigation: The company noted that similar patent litigation against other generic drug filers for DOJOLVI® remains pending.